Signal brief

The U.S. FDA approved an expanded indication for CAMZYOS to treat symptomatic obstructive hypertrophic cardiomyopathy in both adults and pediatric patients. This regulatory milestone broadens CAMZYOS' addressable patient pool, potentially boosting adoption and sales for BMS's cardiovascular franchise, depending on payer coverage, physician uptake, and real-world efficacy.

• FDA expands CAMZYOS indication to symptomatic oHCM in adults and pediatric patients. Broadens eligible patient pool and potential revenue.
• Expansion could meaningfully increase CAMZYOS addressable market. Impact depends on payer coverage and real-world uptake.
• Princeton, NJ-based press release confirms regulatory milestone. No financial terms disclosed.
• Investors will monitor CAMZYOS sales trajectory and FDA label utilization. Pediatric expansion may require physician adoption and dosing guidance.